Pharmacokinetic modeling of recombinant interleukin-2 in patients with human immunodeficiency virus infection (Q45752594)

15 December 2017

title

Pharmacokinetic modeling of recombinant interleukin-2 in patients with human immunodeficiency virus infection (English)

1 reference

15 December 2017

1 reference

Piscitelli SC

1

1 reference

15 December 2017

Forrest A

2

1 reference

15 December 2017

Vogel S

3

1 reference

15 December 2017

Chaitt D

4

1 reference

15 December 2017

Metcalf J

5

1 reference

15 December 2017

Stevens R

6

1 reference

15 December 2017

Baseler M

7

1 reference

15 December 2017

Davey RT

8

1 reference

15 December 2017

Kovacs JA

9

1 reference

15 December 2017

language of work or name

English

0 references

publication date

1 November 1998

1 reference

15 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

15 December 2017

volume

64

1 reference

15 December 2017

issue

5

1 reference

15 December 2017

page(s)

492-498

1 reference

15 December 2017

Immune-based therapies for treatment of HIV infection

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990132-1

Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990132-1

Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990132-1

Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990132-1

Interleukin-2 in the treatment of HIV disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990132-1

Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990132-1

Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990132-1

Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990132-1

A program package for simulation and parameter estimation in pharmacokinetic systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990132-1

Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990132-1

Disposition of recombinant human granulocyte colony-stimulating factor in children with severe chronic neutropenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990132-1

Phase I trial of subcutaneous recombinant macrophage colony-stimulating factor: clinical and immunomodulatory effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990132-1

Physiologic indirect response models characterize diverse types of pharmacodynamic effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990132-1

10.1016/S0009-9236(98)90132-1

7 January 2021

Identifiers

DOI

1 reference

15 December 2017

PubMed ID

9834041

1 reference

15 December 2017